Dr. David Cohn discusses cost-effectiveness ovarian cancer study

Description: An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer may not be cost effective.
Shared By : osumedicalcenter
Posted on : 08/12/11
Added : 6 years ago
Category : Ovarian Cancer

More From osumedicalcenter

Nothing found.